Bank Of New York Mellon Corp Landos Biopharma, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.6 - $1.5 $10,189 - $25,473	-16,982 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.44 - $5.22 $5,764 - $20,895	4,003 Added 30.84%	16,982 $25,000
Q4 2021 Feb 11, 2022	SELL	$4.7 - $15.0 $9,277 - $29,610	-1,974 Reduced 13.2%	12,979 $63,000
Q3 2021 Nov 12, 2021	BUY	$9.77 - $15.77 $9,027 - $14,571	924 Added 6.59%	14,953 $218,000
Q2 2021 Aug 11, 2021	BUY	$9.26 - $12.53 $35,623 - $48,202	3,847 Added 37.78%	14,029 $162,000
Q1 2021 May 13, 2021	BUY	$9.47 - $16.26 $96,423 - $165,559	10,182 New	10,182 $98,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.